ArticleAllergy2024
Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population-based cohort study.
Article in Allergy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative efficacy of pediatric atopic dermatitis treatments: a network meta-analysis highlighting dupilumab and pimecrolimus for SCORAD and EASI improvement.Frontiers in immunology · 2026Pooled it
- Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension Study.Advances in therapy · 2026Trial
- Defining the Potential for Disease Modification in Atopic Dermatitis.American journal of clinical dermatology · 2026Review
- Dupilumab's Real-World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis.The Australasian journal of dermatology · 2026Article
- The era of advanced therapeutics for pediatric atopic dermatitis - can early systemic intervention reduce the type 2 inflammatory response and modify the atopic march?Current opinion in pediatrics · 2026Review
- Multidisciplinary Delphi Consensus on management of children with moderate-severe atopic dermatitis.Italian journal of pediatrics · 2026Article
- Atopic Comorbidities and Topical Steroids in Early Childhood Atopic Dermatitis: Are We Missing a Piece of the Puzzle?Clinical reviews in allergy & immunology · 2026Review
- Impact of Dupilumab on the Skin Microbiome in Children Aged 6-12 years with Moderate-to-Severe Atopic Dermatitis.Journal of asthma and allergy · 2026Article
- Retrospective Study of Severe Atopic Disease in Young Children (0-5 Years) Managed with Dupilumab Highlights Significant Comorbidities.Children (Basel, Switzerland) · 2025Article
- Bidirectional Relationship Between Atopic Dermatitis and Psychiatric Comorbidities in Individuals of European Ancestry: A Mendelian Randomization Study.Acta dermato-venereologica · 2025Article
- Risk of infantile atopic dermatitis in neonatal lupus erythematosus: a retrospective cohort study.Frontiers in immunology · 2025Article
- Skin Care Supports Overall Well-Being.Clinical, cosmetic and investigational dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundDupilumab is the first and only biologic agent approved for the treatment of atopic dermatitis (AD) in pediatric patients aged from 6 months to 17 years. The study aimed to evaluate the impact of dupilumab on the occurrence of comorbidities in pediatric patients with AD.
methodsIn this population-based cohort study, we utilized electronic health records from multiple healthcare organizations across the United States. Pediatric patients (<18 years of age) with a diagnosis of AD initiating dupilumab were propensity-score matched 1:1 to those initiating other systemic agents (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, or systemic corticosteroids). The primary outcomes were new-onset comorbidities emerging during the study period measured by the risk ratio (RR) and its confidence interval (CI). Subgroup analyses were stratified by age (0-5 years, 6-11 years, and 12-17 years), sex, and race.
resultsA total of 3575 pediatric patients with AD treated with dupilumab were matched to 3575 patients treated with other systemic agents. The dupilumab cohort was associated with a lowered risk of new-onset atopic comorbidities (including asthma [RR, 0.72; 95% CI, 0.59-0.89] and allergic rhinitis [RR, 0.62; 95% CI, 0.52-0.74]), infections (e.g., skin and soft tissue infection [RR, 0.70; 95% CI, 0.63-0.76] and respiratory tract infection [RR = 0.56; 95% CI, 0.51-0.61]), psychiatric disorders (e.g., mood disorder [RR, 0.52; 95% CI, 0.39-0.70] and anxiety [RR, 0.57; 95% CI, 0.46-0.70], sleep disturbance [RR, 0.60; 95% CI, 0.47-0.77]), neurologic and developmental disorders (e.g., attention deficit hyperactivity disorder [RR, 0.54; 95% CI, 0.38-0.75]). Furthermore, the positive effects are found to be more pronounced in younger children (aged 0-5 years) with AD.
conclusionsTreatment with dupilumab compared to systemic agents resulted in reductions in AD-related comorbidities in pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.